Arginine decarboxylase mutant and its application in 1,4-butanediamine production
By performing site-directed amino acid mutations on arginine decarboxylase, a mutant with high activity and high pH tolerance was created, solving the problems of low catalytic activity and poor pH tolerance in existing technologies, and realizing the efficient biosynthesis of 1,4-butanediamine.
Patent Information
- Application Number
- CN202610543805.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-23
- Publication Date
- 2026-07-07
AI Technical Summary
In existing technologies, the low catalytic activity and poor pH tolerance of arginine decarboxylase limit the industrial production potential of 1,4-butanediamine via enzymatic methods.
By performing site-directed amino acid residue mutations on wild-type AdiA from Escherichia coli through genetic engineering, a mutant of arginine decarboxylase with high activity and high pH tolerance was obtained. Specifically, the lysine at position 477 was changed to histidine and the asparagine at position 645 was changed to glutamic acid, forming the K477H/N645E mutant.
The catalytic activity and pH tolerance of arginine decarboxylase were improved, increasing its catalytic activity by 7.5 times under neutral pH conditions, making it suitable for the biotransformation conditions of 1,4-butanediamine and achieving efficient biosynthesis.
Smart Images

Figure CN122344568A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of bioengineering, and specifically relates to an arginine decarboxylase mutant and its application in the production of 1,4-butanediamine. Background Technology
[0002] 1,4-Butanediamine, also known as putrescine, is a bioactive amino acid derivative widely found in living organisms. It has significant applications in engineering plastics, pharmaceuticals, surfactants, and the synthesis of agrochemicals. 1,4-Butanediamine can be condensed with adipic acid to form the high-performance polyamide material Nylon-4,6, which possesses advantages such as high melting point, high crystallinity, high heat resistance, and high mechanical strength. It is widely used in textiles, pharmaceuticals, electronics, automotive manufacturing, and aerospace. Therefore, 1,4-Butanediamine has a very broad market application scope and industrial application value.
[0003] Currently, the large-scale production of 1,4-butanediamine mainly relies on chemical synthesis based on the hydrogenation reaction of succinic anhydride and hydrogen cyanide. Succinic anhydride is primarily synthesized from hydrogen cyanide and acrylonitrile under an alkaline catalyst. Due to the toxicity of hydrogen cyanide and the high equipment requirements of this process, the succinic anhydride synthesis technology is highly monopolized. Currently, DSM in the Netherlands possesses the most advanced succinic anhydride synthesis process, with high-purity succinic anhydride priced at 250,000 RMB / ton, severely limiting the potential for large-scale 1,4-butanediamine production in China. In addition, 1,4-butanediamine can also be synthesized from 1,4-succinic acid, pyrrole and hydroxylamine hydrochloride, 2,5-diaminovaleric acid, 1,4-dibromobutylamine, and 1,4-butanediol, but the scale is small, hindering large-scale industrial production. Therefore, finding a green and efficient method for synthesizing 1,4-butanediamine using renewable resources is crucial. Currently, research both domestically and internationally focuses on producing 1,4-butanediamine using bio-fermentation. This involves modifying microbial metabolic pathways to achieve the biosynthesis of 1,4-butanediamine from glucose. However, research on the biosynthesis of 1,4-butanediamine is still limited, and the yield is low, preventing its application in industrial production.
[0004] The enzymatic synthesis of 1,4-butanediamine is a novel method that utilizes specific enzymes produced by microorganisms, using L-arginine as a starting substrate, to specifically catalyze the synthesis of 1,4-butanediamine. Due to its higher substrate specificity, milder reaction conditions, and avoidance of the biotoxicity of the product 1,4-butanediamine to microbial cell fermentation, the enzymatic method holds significant potential for the industrial-scale production of 1,4-butanediamine. However, in existing technologies, arginine decarboxylase (AdiA), the key enzyme in the synthesis of 1,4-butanediamine, suffers from bottlenecks in industrial applications, such as low catalytic activity and poor pH tolerance. This leads to low yields and low conversion rates in the enzymatic production of 1,4-butanediamine, severely limiting its industrial-scale production potential. Therefore, developing AdiA with high catalytic activity and high pH tolerance is of great significance for the green biomanufacturing of 1,4-butanediamine. Summary of the Invention
[0005] The purpose of this invention is to: 1) provide a mutant of arginine decarboxylase with high activity and enhanced pH tolerance using genetic engineering and protein engineering; 2) provide a recombinant vector or host bacterium expressing the mutant of arginine decarboxylase with high activity and enhanced pH tolerance; and 3) provide the application of the mutant of arginine decarboxylase with high activity and enhanced pH tolerance in the production of 1,4-butanediamine.
[0006] The technical solution adopted by the present invention to solve the above-mentioned technical problems is as follows: This invention uses strains Escherichia coli Wild-type AdiA (EcAdiA) (accession number: P28629) was used as the parent (its amino acid sequence and gene sequence are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively). By site-directed mutagenesis of key amino acid residues, a mutant of arginine decarboxylase with high activity and enhanced pH tolerance was obtained.
[0007] In one embodiment of the present invention, the arginine decarboxylase mutant is prepared by changing the amino acid residue at position 477 from lysine to histidine, as shown in SEQ ID NO:1, with the amino acid sequence shown in SEQ ID NO:3, named K477H; or changing the amino acid residue at position 645 from asparagine to glutamic acid, with the amino acid sequence shown in SEQ ID NO:5, named N645E; or integrating the above mutations into the same amino acid sequence, with the amino acid sequence shown in SEQ ID NO:5, named K477H / N645E.
[0008] The present invention also provides a gene sequence encoding the highly active, high pH-tolerant arginine decarboxylase mutant, as shown in SEQ ID NO:6.
[0009] The present invention also provides a recombinant expression vector carrying the arginine decarboxylase mutant gene.
[0010] The present invention also provides genetically engineered bacteria carrying the arginine decarboxylase mutant gene or the recombinant expression vector.
[0011] In one embodiment of the present invention, the genetically engineered bacteria uses Escherichia coli as a host.
[0012] Preferably, the recombinant expression vector is an Escherichia coli expression vector pET series vector.
[0013] Furthermore, the present invention provides a method for preparing the arginine decarboxylase mutant, specifically comprising the following steps: 1) Using the genome of Escherichia coli BL21(DE3) as a template, the coding sequence of arginine decarboxylase was obtained by PCR amplification. Its amino acid sequence is shown in SEQ ID NO:1 and its nucleotide sequence is shown in SEQ ID NO:2. The nucleotide coding sequence was ligated between the Nde I and Xho I restriction sites of the expression vector to obtain the recombinant plasmid. 2) Using recombinant plasmids as templates, design mutation primers for site-directed mutagenesis, perform site-directed mutagenesis PCR amplification, and then circularize and ligate the reaction products to construct a mutant expression vector. 3) The successfully constructed mutant expression vector was introduced into the engineered strain, and the validated positive single clones were selected for induced expression culture; 4) Collect the cultured bacterial cells, resuspend them in solution, break the bacterial cells, centrifuge to remove cell debris, and purify the supernatant by nickel column (Ni-NTA) affinity chromatography to obtain the arginine decarboxylase mutant.
[0014] The present invention also provides a recombinant cell that expresses guanidine amino acid enzyme SpeB.
[0015] In one embodiment of the present invention, the amino acid sequence of the guanidine amino acid enzyme SpeB is shown in SEQ ID NO:7, and its gene sequence is shown in SEQ ID NO:8.
[0016] The present invention also provides a method for producing 1,4-butanediamine, wherein the method is any one of (a) to (b): (a) The recombinant cells were added to a reaction system containing L-arginine to prepare 1,4-butanediamine; (b) The arginine decarboxylase mutant and the guanidine amino acid enzyme with the amino acid sequence shown in SEQ ID NO:7 were added to a reaction system containing L-arginine to prepare 1,4-butanediamine.
[0017] The present invention also provides the use of the above-mentioned arginine decarboxylase mutant, or the above-mentioned gene, or the above-mentioned recombinant vector, or the above-mentioned genetically engineered bacteria, or the above-mentioned recombinant cells, or the above-mentioned whole-cell catalyst in the preparation of products containing 1,4-butanediamine. Beneficial effects
[0018] This invention modifies the arginine decarboxylase gene through rational site-directed mutagenesis, changing the amino acid residue at position 477 from lysine to histidine and the amino acid residue at position 645 from asparagine to glutamic acid. The resulting arginine decarboxylase mutant, EcAdiA_K477H / N645E, exhibits significantly improved catalytic activity and pH tolerance. The catalytic activity of EcAdiA_K477H / N645E at pH 7.0 is increased by 7.5 times, making it more suitable for the biotransformation conditions of 1,4-butanediamine and laying the foundation for the efficient biosynthesis of 1,4-butanediamine. Attached Figure Description
[0019] Figure 1 Enzyme activity characterization of wild-type and mutant arginine decarboxylase. Detailed Implementation
[0020] The method of the present invention is described below through specific implementation schemes. Unless otherwise specified, the technical means used in the specific embodiments of the present invention are all methods known to those skilled in the art.
[0021] In specific embodiments of the present invention, the obtained mutants are defined as follows: The naming principle for mutants is as follows: The mutant obtained by the substitution (mutation) is represented by "original amino acid residue + residue position + substituted amino acid residue" in the amino acid sequence. For example, "K477H" indicates a mutant obtained by replacing lysine (Lys) with histidine (His) in the parent EcAdiA amino acid sequence at position 477; K477H / N645E indicates a mutant obtained by mutating both amino acid residues at positions 477 and 645 (Asn replaced by Glu). The naming method for multi-site mutants obtained by mutations at two or more residue positions follows the same principle.
[0022] Table 1 shows the primer sequences involved in the examples.
[0023] Enzyme activity (U): The amount of enzyme required to catalyze the synthesis of 1 μmol of 1,4-butanediamine per unit time (min) under standard reaction conditions.
[0024] Relative enzyme activity definition: The enzyme activity of wild-type arginine decarboxylase is defined as 100%, and the enzyme activity of other mutants is measured and calculated based on this standard.
[0025] The method for determining arginine decarboxylase activity is as follows: (1) Prepare a 1 mL enzyme activation reaction system. Using 25 mmol / L L-arginine as the substrate, add 30 μg / mL of purified enzyme (arginine decarboxylase or its mutant), 30 μg / mL of purified enzyme (guanidine amino acid enzyme), 0.5 mmol / L pyridoxal phosphate (PLP), 4 mmol / L MgSO4, and 4 mmol / L MnCl2. React at 37 ℃ in potassium phosphate buffer (pH 5.5-7.0) for 10 min, then boil for 10 min to inactivate the enzyme. Centrifuge the reaction product, pass it through a membrane, dilute it to a certain concentration, and then perform HPLC detection.
[0026] (2) HPLC detection conditions: Chromatograph: Agilent 1260; Detector: Differential detector; Differential detector temperature: 30℃; Column: Waters Xbridge BEHAmide (2.5 μm, 4.6 × 250 mm); Column temperature: 45℃; Mobile phase: Acetonitrile-phosphate buffer (75:45); Flow rate: 1 mL / min.
[0027] Example 1: Preparation of arginine decarboxylase mutant
[0028] (1) Construction of recombinant plasmid pET-22b(+)-EcAdiA Using the *E. coli* BL21(DE3) genome as a template, the arginine decarboxylase gene fragment adiA (gene sequence shown in SEQ ID NO:2) was amplified using primers EcAdiA-F and EcAdiA-R listed in Table 1. The adiA gene fragment was then double-digested with Nde I and Xho I, and ligated into the Nde I and Xho I-digested pET-22b(+) expression plasmid. The ligation product was introduced into *E. coli* JM109, and screening was performed by colony PCR and gene sequencing to finally obtain the recombinant plasmid pET-22b(+)-EcAdiA.
[0029] (2) Construction of mutant expression vector Using the recombinant plasmid pET-22b(+)-EcAdiA obtained in step (1) as a template, mutation primers for point mutation were designed, and then site-directed mutagenesis PCR amplification reaction was performed to construct the mutation expression vector.
[0030] The mutation primers include two pairs of primers: K477H-F / R and N645E-F / R, as shown in Table 1.
[0031] PCR amplification: The target gene pET-22b-EcAdiA was mutated using the KOD-Plus mutant kit (purchased from Toyobo (Shanghai) Biotechnology Co., Ltd.). The total volume of the reaction system was 25 μL, and the components of the reaction system are shown in Table 2.
[0032] Table 2 PCR amplification reaction system Components Added volume (μL) KOD-plus polymerase 0.5 KOD buffer 2.5 Substrate (dNTP) 2.5 Upstream primer (10 μM) 0.75 Downstream primer (10 μM) 0.75 pET-22b-EcAdiA recombinant plasmid (50 ng / μL) 1 <![CDATA[Sterile water (ddH2O)]]> 17 The PCR reaction program was as follows: 94 °C, 2 min (pre-denaturation); 98 °C, 10 s (denaturation); 68 °C, 7 min (extension); 7 cycles; 4 °C, ∞ (storage).
[0033] After the reaction, 2 μL of the PCR product was taken for agarose gel electrophoresis to verify the bands. 0.4 μL of Dpn I was added to the correctly verified PCR product, and the digestion reaction was carried out at 37℃ for 1 h. After the digestion reaction, the gene fragment of the digested product was circularized and ligated. The total volume of the circularization system was 15 μL, and the components are shown in Table 3.
[0034] Table 3 Cyclic Linkage Reaction System Components Added volume (μL) Enzyme digestion products 3 Ligation high 5 T4 Polynucletide Kinase 1 <![CDATA[Sterile water (ddH2O)]]> 6 After gently mixing the above cyclization system, it was placed at 37°C for 1 h to react.
[0035] After the reaction is complete, the above reaction products are converted to... E. coli JM109 competent cells were then selected for plasmid extraction and DNA sequencing. Individuals with correct sequencing results were considered successfully constructed mutant expression vectors. This invention yielded three mutant expression vectors through the aforementioned steps, including two single-point mutation expression vectors: pET-22b(+)-EcAdiA_K477H and pET-22b(+)-EcAdiA_N645E, and one double-point mutation expression vector: pET-22b(+)-EcAdiA_K477H / N645E.
[0036] (3) Expression and purification of mutant enzymes The recombinant vectors pET-22b(+)-EcAdiA, pET-22b(+)-EcAdiA_K477H, pET-22b(+)-EcAdiA_N645E, and pET-22b(+)-EcAdiA_K477H / N645E were transformed into Escherichia coli BL21(DE3) cells to obtain recombinant arginine decarboxylase strains E1, E2, E3, and E4, which were then stored in glycerol tubes for later use.
[0037] Recombinant strains E1, E2, E3, and E4, preserved in glycerol tubes, were streaked onto plates for isolation. Single colonies of each strain were then inoculated into LB medium containing 100 μg / mL ampicillin and incubated overnight at 37°C and 220 rpm to obtain seed culture. The seed culture was then inoculated at a volume ratio of 2% into TB medium containing 100 μg / mL ampicillin and cultured at 37°C until OD... 600 The value was 0.6–0.8, then the temperature was lowered to 25°C, and IPTG with a final concentration of 0.3 mM was added to induce fermentation for 16–18 h to obtain the fermentation broth.
[0038] The four fermentation broths were centrifuged at 4℃ and 8000 rpm for 20 min to collect the cells. The cells were resuspended in solution A (20 mM Tris-HCl, pH 7.4, 500 mM NaCl, 20 mM imidazole, 2 mM DTT), lysozyme (final concentration 200 µg / mL) was added, and the mixture was placed on ice for 30 min. Then, the cells were sonicated on ice (2 s, 3 s interval, 400 W). Finally, the cells were centrifuged at low temperature and high speed (4℃, 12000 r / min) to remove cell debris and obtain the supernatant.
[0039] The four supernatants were subjected to Ni affinity chromatography: 1 mL of Ni-NTA resin (QIAGEN) was added to each of the four open columns; the resin was equilibrated with 20 mL of solution A, and then the supernatant and 1 mL of resin were incubated at 4 °C for 40–60 min; the mixture was passed through the open column, and the protein-bound resin was retained; the resin was then washed with 20 mL of solution A; finally, the protein was eluted with 15 mL of solution B (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 400 mM imidazole, 2 mM DTT). The eluted protein was transferred to 1×PBS buffer (pH 7.4) using an ultrafiltration tube to remove imidazole and other metal ions from the eluent. The four proteins were stored at 4 °C for later use. The four proteins include: wild-type EcAdiA (parent) and three mutants of EcAdiA, namely K477H, N645E and K477H / N645E. The amino acid sequence and gene sequence of mutant K477H / N645E are shown in SEQ ID NO:3 and SEQ ID NO:4, respectively.
[0040] Example 2: Activity determination of arginine decarboxylase and its mutants
[0041] Under standard reaction conditions (potassium phosphate buffer (pH 5.5-7.0), 25 mmol / L L-arginine, 4 mmol / L MgSO4, 4 mmol / L MnCl2, 30 μg / mL purified enzyme (arginine decarboxylase or its mutant), 30 μg / mL purified enzyme (guanidine aminotransferase), 0.5 mmol / L PLP, reaction at 37℃ for 5 min), the enzyme activities of the purified mutant and wild-type arginine decarboxylase were determined according to the aforementioned HPLC method for detecting enzyme reaction systems. The results are as follows: Figure 1 As shown, mutant K477H / N645E exhibited the highest enzyme activity at pH 7.0, reaching 15.7 U / mg, a 7.5-fold increase compared to the wild-type enzyme activity. This significantly improved the stability and activity of arginine decarboxylase EcAdiA in a neutral pH environment. The enzyme activities of mutants K477H and N645E at pH 7.0 increased from 2.1 U / mg to 7.56 U / mg and 9.87 U / mg, respectively. Therefore, the arginine decarboxylase mutants obtained in this invention demonstrate improved enzyme activity and stability within a neutral pH range, making them more suitable for the environmental requirements of industrial synthesis of 1,4-butanediamine and laying the foundation for efficient biosynthesis of 1,4-butanediamine.
[0042] Example 3: Construction of recombinant guanidine amino acid enzyme strain Using the *E. coli* BL21(DE3) genome as a template, the arginine decarboxylase gene fragment speB (amino acid sequence shown in SEQ ID NO:7, gene sequence shown in SEQ ID NO:8) was amplified using primers SpeB-F and SpeB-R listed in Table 1. The speB gene fragment was then double-digested with Nde I and Xho I, and ligated into the Nde I and Xho I double-digested pET-22b(+) expression plasmid. The ligation product was introduced into *E. coli* JM109, and screening was performed by colony PCR and gene sequencing to obtain the recombinant plasmid pET-22b(+)-SpeB. The recombinant plasmid pET-22b(+)-SpeB was transformed into *E. coli* BL21(DE3) to obtain the guanidine amino acid enzyme recombinant strain E5, which was stored in glycerol tubes for later use.
[0043] Example 4: Preparation of 1,4-Butanediamine using arginine decarboxylase and its mutant recombinant bacteria in whole cells Shake-flask fermentation of recombinant bacteria containing arginine decarboxylase and guanidine amino acid enzyme
[0044] After streaking the arginine decarboxylase recombinant bacteria E1 and E4 and the guanidine amino acid enzyme recombinant bacteria E5, which were preserved in glycerol tubes, onto plates for isolation, single colonies of each strain were picked and inoculated into LB medium containing 100 μg / mL ampicillin and cultured overnight at 37°C and 220 rpm to obtain seed culture. The seed culture was then inoculated at a volume ratio of 2% into TB medium containing 100 μg / mL ampicillin and cultured at 37°C until OD. 600 The concentration was set to 0.6–0.8, then the temperature was lowered to 25°C, and IPTG was added to a final concentration of 0.3 mM for induction for 16–18 h to obtain the fermentation broth. The fermentation broth was centrifuged at 4°C and 8000 rpm for 20 min, and the cells were collected to obtain wet cells E1, E4, and E5, respectively.
[0045] Preparation of 1,4-Butanediamine from Whole Cells of Escherichia coli using Arginine Decarboxylase and Guanidine Aminoase In a 1L reaction system, E1 or E4 cells had a wet weight of 8 g / L, E5 cells had a wet weight of 4 g / L, L-arginine was 300 g / L (pH adjusted to 6.0 with hydrochloric acid), 4 mmol / L MgSO4, 4 mmol / L MnCl2, and 0.5 mmol / L PLP were added. The reaction was carried out at 37℃ for 12 h, and the concentration of 1,4-butanediamine in the reaction solution was detected by HPLC. The yields of 1,4-butanediamine produced from L-arginine by EcAdiA wild-type and K477H / N645E mutant are shown in Table 4. After 12 h of conversion, the molar conversion rate of EcAdiA wild-type was 28.6%, while the molar conversion rate of K477H / N645E mutant reached 100%, with complete conversion of L-arginine and a yield of 151.8 g / L of 1,4-butanediamine.
[0046] Table 4. Whole-cell catalytic yields of 1,4-butanediamine from wild-type EcAdiA and K477H / N645E mutants cell L-arginine addition (g / L) 1,4-Butanediamine yield (g / L) EcAdiA (E1) 300 43.5 K477H / N645E (E4) 300 151.8 Example 5: Preparation of 1,4-Butanediamine using arginine decarboxylase and its mutant enzyme
[0047] (1) Shake-flask fermentation of recombinant bacteria containing arginine decarboxylase and guanidine amino acid enzyme After streaking the arginine decarboxylase recombinant bacteria E1 and E4 and the guanidine amino acid enzyme recombinant bacteria E5, which were preserved in glycerol tubes, onto plates for isolation, single colonies of each strain were picked and inoculated into LB medium containing 100 μg / mL ampicillin and cultured overnight at 37°C and 220 rpm to obtain seed culture. The seed culture was then inoculated at a volume ratio of 2% into TB medium containing 100 μg / mL ampicillin and cultured at 37°C until OD. 600The concentration was set to 0.6–0.8, then the temperature was lowered to 25°C, and IPTG was added to a final concentration of 0.3 mM for induction for 16–18 h to obtain the fermentation broth. The fermentation broth was centrifuged at 4°C and 8000 rpm for 20 min, and the cells were collected to obtain wet cells E1, E4, and E5, respectively.
[0048] (2) Preparation of arginine decarboxylase and guanidine amino acid enzyme solutions The wet cells were resuspended in pure water at a bacterial concentration of 400 g / L. After resuspending, lysozyme (final concentration of 200 µg / mL) was added and the cells were placed on ice for 30 min. Then, the cells were sonicated on ice (2 s, 3 s interval, 400 W). Finally, the cells were centrifuged at low temperature and high speed (4℃, 12000 r / min) to remove cell debris and obtain the supernatant, which yielded the enzyme solutions of arginine decarboxylase and guanidine amino acid enzyme.
[0049] (3) Preparation of 1,4-butanediamine using arginine decarboxylase and guanidine amino acid enzyme solutions In a 1L reaction system, 20 mL of EcAdiA wild-type or mutant K477H / N645E enzyme solution, 10 mL of guanidine aminotransferase solution, 300 g / L L-arginine (adjusted to pH 6.0 with hydrochloric acid), 4 mmol / L MgSO4, 4 mmol / L MnCl2, and 0.5 mmol / L PLP were added. The reaction was carried out at 37℃ for 12 h, and the concentration of 1,4-butanediamine in the reaction solution was detected by HPLC. The yields of 1,4-butanediamine produced from L-arginine by EcAdiA wild-type and K477H / N645E mutant are shown in Table 5. After 12 h of conversion, the molar conversion rate of EcAdiA wild-type was 44.4%, and the molar conversion rate of K477H / N645E mutant reached 100%, with complete conversion of L-arginine and a yield of 151.8 g / L of 1,4-butanediamine.
[0050] Table 5. Yields of 1,4-butanediamine catalyzed by enzyme solutions of wild-type EcAdiA and K477H / N645E mutants enzyme solution L-arginine addition (g / L) 1,4-Butanediamine yield (g / L) EcAdiA(E1) 300 67.4 K477H / N645E (E4) 300 151.8 Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.
Claims
1. An arginine decarboxylase mutant, characterized in that, The arginine decarboxylase mutant was obtained by mutating amino acid residues at positions 477 and / or 645 of the arginine decarboxylase, as shown in SEQ ID NO:
1.
2. The arginine decarboxylase mutant according to claim 1, characterized in that, The arginine decarboxylase mutant is prepared by changing the amino acid residue at position 477 from lysine to histidine, as shown in SEQ ID NO:1, with the amino acid sequence shown in SEQ ID NO:3, named K477H; or changing the amino acid residue at position 645 from asparagine to glutamic acid, with the amino acid sequence shown in SEQ ID NO:4, named N645E; or integrating the above mutations into the same amino acid sequence, with the amino acid sequence shown in SEQ ID NO:5, named K477H / N645E.
3. A gene encoding the arginine decarboxylase mutant of claim 1 or 2.
4. A recombinant vector carrying the gene of claim 3.
5. Genetically engineered bacteria carrying the gene of claim 3 or the recombinant vector of claim 4.
6. A recombinant cell, characterized in that, The cells expressed the guanidine amino acid enzyme SpeB.
7. The recombinant cell according to claim 6, characterized in that, The amino acid sequence of the guanidine amino acid enzyme SpeB is shown in SEQ ID NO:7, and the nucleotide sequence is shown in SEQ ID NO:
8.
8. A catalyst, characterized in that, The chemical agent contains the recombinant cells or cell disruption solution as described in claim 5 or 7.
9. A method for producing 1,4-butanediamine, characterized in that, The method is any one of (a) to (b): (a) The recombinant cells of claims 5 and 7 are added to a reaction system containing L-arginine to prepare 1,4-butanediamine; (b) The arginine decarboxylase mutant of claim 1 or 2 and the guanidine amino acid enzyme with the amino acid sequence shown in SEQ ID NO:7 are added to a reaction system containing L-arginine to prepare 1,4-butanediamine.
10. The use of the arginine decarboxylase mutant of claim 1 or 2, or the gene of claim 3, or the recombinant vector of claim 4, or the genetically engineered bacteria of claim 5, or the recombinant cell of claim 6 or 7, or the catalyst of claim 8 in the preparation of a product containing 1,4-butanediamine.
